NeuroCOVID - A Study of Activation and Inhibition of the Immune and Coagulation Systems, the Presence of Biochemical (Blood / CSF) and Structural Brain Changes and Their Association With Long-term Cognitive Dysfunction in Intensive Care-requiring Covid-19 Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Covid19
- Sponsor
- Karolinska University Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder
- Last Updated
- 5 years ago
Overview
Brief Summary
Critically ill patients requiring intensive care suffer to a large extent from cognitive deficits involving higher brain functions that primarily affect memory, learning and the ability to concentrate. While the background to this effect is not fully understood, there are growing evidence to support mechanisms related to neuro inflammation and changes in blood flow with concomitant ischemic brain damage. Patients with covid-19 often suffer from severe inflammatory activity with an increased risk of coagulation abnormalities and brain damage. Covid-19 patients requiring intensive care develope more severe impairment of neurological and cognitive function than critically ill intensive care patients who have not covid-19. This project therefore aims to map the link between inflammation, immunology and coagulation systems as well as biochemical and structural changes in the brain with cognitive effects in patients in intensive care for covid-19.
Investigators
Lars I Eriksson
Professor
Karolinska University Hospital
Eligibility Criteria
Inclusion Criteria
- •Age ≥18 years
- •Need for Intensive care
- •Positive PCR test for SARS-CoV-2
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder
Time Frame: Up to 12 months
The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder
Time Frame: Up to 12 months
The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder
Time Frame: Up to 12 months
Secondary Outcomes
- Blood biomarker changes of neurological impact(Up to 3 months)
- Clinical course - Pulmonary gas exchange(Up to 3 months)
- Clinical course - Lung function recording(Up to 3 months)
- The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder(Up to 12 months)
- The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder(Up to 12 months)
- The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder(Up to 12 month)
- Blood biomarker changes of inflammation impact(Up to 3 months)
- Neuroradiological changes(Up to 3 months)
- Patient characteristics(Up to 3 months)